blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4153133

EP4153133 - INJECTABLE PHARMACEUTICAL COMPOSITIONS AND USES THEREOF [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  06.10.2023
Database last updated on 01.04.2026
FormerGrant of patent is intended
Status updated on  27.07.2023
FormerRequest for examination was made
Status updated on  24.02.2023
FormerThe international publication has been made
Status updated on  26.11.2021
Formerunknown
Status updated on  04.06.2021
Most recent event   Tooltip20.01.2026New entry: Despatch of communication that the patent will be maintained as amended 
Applicant(s)For all designated states
Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer / NL
[2023/13]
Inventor(s)01 / VALLE COLON, Brenda, L
Rahway, NJ 07065 / US
02 / FREEHAUF, Keith
Madison, NJ 07940 / US
03 / KULCZAR, Christopher, D
Rahway, NJ 07065 / US
04 / GUERINO, Frank
Madison, NJ 07940 / US
 [2023/13]
Representative(s)Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer / NL
[2023/13]
Application number, filing date21727821.719.05.2021
[2023/13]
WO2021EP63236
Priority number, dateEP2020017559720.05.2020         Original published format: EP 20175597
[2023/13]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021233967
Date:25.11.2021
Language:EN
[2021/47]
Type: A1 Application with search report 
No.:EP4153133
Date:29.03.2023
Language:EN
The application published by WIPO in one of the EPO official languages on 25.11.2021 takes the place of the publication of the European patent application.
[2023/13]
Type: B1 Patent specification 
No.:EP4153133
Date:08.11.2023
Language:EN
[2023/45]
Search report(s)International search report - published on:EP25.11.2021
ClassificationIPC:A61K9/00, A61K9/10, A61K9/14, A61K9/16, A61K9/50, A61K31/422, A61K31/7028, A61P33/00, A61P33/10, A61P33/14
[2023/13]
CPC:
A61P33/10 (EP,IL); A61K31/42 (EP,IL,US); A61K31/365 (EP,IL);
A61K31/366 (US); A61K31/422 (EP,IL); A61K9/0019 (EP,IL,US);
A61K9/10 (EP,IL); A61K9/14 (EP,IL); A61K9/1647 (EP,IL,US);
A61K9/1682 (US); A61K9/5031 (EP,IL); A61K9/5084 (EP,IL);
A61P33/00 (EP,IL); A61P33/14 (EP,IL); A61K2300/00 (IL) (-)
C-Set:
A61K31/365, A61K2300/00 (EP);
A61K31/422, A61K2300/00 (EP);
A61K31/42, A61K2300/00 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/13]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:INJIZIERBARE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN UND VERWENDUNGEN DAVON[2023/13]
English:INJECTABLE PHARMACEUTICAL COMPOSITIONS AND USES THEREOF[2023/13]
French:COMPOSITIONS PHARMACEUTIQUES INJECTABLES ET LEURS UTILISATIONS[2023/13]
Entry into regional phase20.12.2022National basic fee paid 
20.12.2022Designation fee(s) paid 
20.12.2022Examination fee paid 
Examination procedure07.11.2022Amendment by applicant (claims and/or description)
20.12.2022Examination requested  [2023/13]
20.12.2022Date on which the examining division has become responsible
28.07.2023Communication of intention to grant the patent
27.09.2023Fee for grant paid
27.09.2023Fee for publishing/printing paid
27.09.2023Receipt of the translation of the claim(s)
Opposition(s)Opponent(s)01  31.07.2024  01.08.2024  ADMISSIBLE
VIRBAC
1ère Avenue, 2065m, L.I.D.
06516 Carros / FR
Opponent's representative
Lavoix
2, place d'Estienne d'Orves
75441 Paris Cedex 09 / FR
 [2024/36]
21.08.2024Invitation to proprietor to file observations on the notice of opposition
19.12.2024Reply of patent proprietor to notice(s) of opposition
17.09.2025Cancellation of oral proceeding that was planned for 24.09.2025
24.09.2025Date of oral proceedings
02.10.2025Despatch of interlocutory decision in opposition
02.10.2025Legal effect of interlocutory decision in opposition
21.01.2026Despatch of communication that the patent will be maintained as amended
Fees paidRenewal fee
21.03.2023Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY19.05.2021
HU19.05.2021
AT08.11.2023
EE08.11.2023
HR08.11.2023
LT08.11.2023
LV08.11.2023
MC08.11.2023
PL08.11.2023
RO08.11.2023
RS08.11.2023
SI08.11.2023
SK08.11.2023
SM08.11.2023
BG08.02.2024
GR09.02.2024
IS08.03.2024
LU19.05.2024
[2025/41]
Former [2025/08]AT08.11.2023
EE08.11.2023
HR08.11.2023
LT08.11.2023
LV08.11.2023
MC08.11.2023
PL08.11.2023
RO08.11.2023
RS08.11.2023
SI08.11.2023
SK08.11.2023
SM08.11.2023
BG08.02.2024
GR09.02.2024
IS08.03.2024
LU19.05.2024
Former [2025/07]AT08.11.2023
EE08.11.2023
HR08.11.2023
LT08.11.2023
LV08.11.2023
MC08.11.2023
PL08.11.2023
RO08.11.2023
RS08.11.2023
SI08.11.2023
SK08.11.2023
SM08.11.2023
BG08.02.2024
GR09.02.2024
IS08.03.2024
Former [2024/50]AT08.11.2023
EE08.11.2023
HR08.11.2023
LT08.11.2023
LV08.11.2023
PL08.11.2023
RO08.11.2023
RS08.11.2023
SI08.11.2023
SK08.11.2023
SM08.11.2023
BG08.02.2024
GR09.02.2024
IS08.03.2024
Former [2024/36]AT08.11.2023
EE08.11.2023
HR08.11.2023
LT08.11.2023
LV08.11.2023
PL08.11.2023
RO08.11.2023
RS08.11.2023
SK08.11.2023
SM08.11.2023
BG08.02.2024
GR09.02.2024
IS08.03.2024
Former [2024/35]AT08.11.2023
EE08.11.2023
HR08.11.2023
LT08.11.2023
LV08.11.2023
PL08.11.2023
RO08.11.2023
RS08.11.2023
SM08.11.2023
BG08.02.2024
GR09.02.2024
IS08.03.2024
Former [2024/33]AT08.11.2023
HR08.11.2023
LT08.11.2023
LV08.11.2023
PL08.11.2023
RS08.11.2023
SM08.11.2023
BG08.02.2024
GR09.02.2024
IS08.03.2024
Former [2024/27]AT08.11.2023
HR08.11.2023
LT08.11.2023
LV08.11.2023
PL08.11.2023
RS08.11.2023
BG08.02.2024
GR09.02.2024
IS08.03.2024
Former [2024/23]AT08.11.2023
LT08.11.2023
BG08.02.2024
GR09.02.2024
IS08.03.2024
Former [2024/21]LT08.11.2023
BG08.02.2024
GR09.02.2024
IS08.03.2024
Former [2024/20]GR09.02.2024
IS08.03.2024
Cited inInternational search[AD] WO2015048371  (ZOETIS LLC et al.)
 [A] WO2009053466  (SCHERING PLOUGH LTD et al.)
 [A] KR20190027349  (INVENTAGE LAB INC et al.)
 [A]   NADJA ROHDICH ET AL: "Field effectiveness and safety of fluralaner plus moxidectin (Bravecto Plus) against ticks and fleas: a European randomized, blinded, multicenter field study in naturally-infested client-owned cats", PARASITES & VECTORS, vol. 11, no. 1, 19 November 2018 (2018-11-19), XP055714293, DOI: 10.1186/s13071-018-3175-z

DOI:   http://dx.doi.org/10.1186/s13071-018-3175-z
by applicantUS2007066617
 WO2005085216
 WO2007079162
 WO2009002809
 WO2009024541
 WO2009003075
 WO2009080250
 WO2010070068
 WO2010079077
 WO2011124998
 WO2015048371
 WO2016138339
 WO2016164487
 US9609869
 US2017239218
 US4916154
 EP0525307
 EP1197207
 WO2019091940
 WO2009063910
 JP2011051977
 WO2019012377
   "Gennaro, Remington: The Science and Practice of Pharmacy", 2000
OppositionWO2019091936
 WO2019050259
 EP3733164
 WO2016138339
 US6340671
 US5733566
 WO2009053466
 GB2558996
 WO2019050259
 WO2016138339
   DORATI ROSSELLA; GENTA IDA; COLZANI BARBARA; MODENA TIZIANA; BRUNI GIOVANNA; TRIPODO GIUSEPPE; CONTI BICE: "Stability Evaluation of Ivermectin-Loaded Biodegradable Microspheres", AAPS PHARMSCITECH, SPRINGER US, NEW YORK, vol. 16, no. 5, 21 February 2015 (2015-02-21), New York , pages 1129 - 1139, XP035604224, DOI: 10.1208/s12249-015-0305-1 * texte en entier *

DOI:   http://dx.doi.org/10.1208/s12249-015-0305-1
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.